Aratana Therapeutics Inc (PETX) to Post Q1 2017 Earnings of ($0.29) Per Share, Jefferies Group Forecasts
Aratana Therapeutics Inc (NASDAQ:PETX) – Equities researchers at Jefferies Group dropped their Q1 2017 earnings per share estimates for Aratana Therapeutics in a research note issued on Thursday. Jefferies Group analyst D. Gu now forecasts that the brokerage will post earnings per share of ($0.29) for the quarter, down from their previous estimate of ($0.28). Jefferies Group also issued estimates for Aratana Therapeutics’ Q2 2017 earnings at ($0.29) EPS, Q3 2017 earnings at ($0.30) EPS, Q4 2017 earnings at ($0.32) EPS, FY2017 earnings at ($1.20) EPS, Q1 2018 earnings at ($0.19) EPS, Q2 2018 earnings at ($0.16) EPS, Q3 2018 earnings at ($0.16) EPS, Q4 2018 earnings at ($0.17) EPS, FY2018 earnings at ($0.69) EPS and FY2019 earnings at ($0.32) EPS.
Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Monday, March 13th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.22. Aratana Therapeutics had a negative return on equity of 19.87% and a negative net margin of 60.32%. The business had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.80 million. During the same quarter in the prior year, the business earned ($0.37) earnings per share. The firm’s quarterly revenue was up 363.5% on a year-over-year basis.
Your IP Address:
PETX has been the topic of several other reports. Stifel Nicolaus cut Aratana Therapeutics from a “buy” rating to a “hold” rating and set a $8.00 price target on the stock. in a research report on Monday, February 6th. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 15th. Finally, William Blair reiterated an “outperform” rating on shares of Aratana Therapeutics in a research report on Thursday, February 9th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $10.25.
Shares of Aratana Therapeutics (NASDAQ:PETX) opened at 5.32 on Monday. The company’s 50-day moving average is $6.66 and its 200 day moving average is $7.87. The firm’s market capitalization is $198.77 million. Aratana Therapeutics has a 52-week low of $4.16 and a 52-week high of $10.73.
In other news, insider Peter Steven St sold 50,000 shares of the company’s stock in a transaction dated Friday, January 27th. The stock was sold at an average price of $7.72, for a total transaction of $386,000.00. Following the sale, the insider now directly owns 632,693 shares in the company, valued at $4,884,389.96. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 6.70% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Broadfin Capital LLC raised its stake in shares of Aratana Therapeutics by 19.7% in the fourth quarter. Broadfin Capital LLC now owns 3,695,442 shares of the biopharmaceutical company’s stock worth $26,533,000 after buying an additional 609,463 shares in the last quarter. Janus Capital Management LLC raised its stake in shares of Aratana Therapeutics by 129.3% in the fourth quarter. Janus Capital Management LLC now owns 1,426,936 shares of the biopharmaceutical company’s stock worth $10,245,000 after buying an additional 804,753 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Aratana Therapeutics during the third quarter worth $11,259,000. Cadence Capital Management LLC raised its stake in shares of Aratana Therapeutics by 2.6% in the fourth quarter. Cadence Capital Management LLC now owns 108,420 shares of the biopharmaceutical company’s stock worth $778,000 after buying an additional 2,745 shares in the last quarter. Finally, Citadel Advisors LLC raised its stake in shares of Aratana Therapeutics by 82.2% in the third quarter. Citadel Advisors LLC now owns 80,547 shares of the biopharmaceutical company’s stock worth $754,000 after buying an additional 36,348 shares in the last quarter. Institutional investors own 75.44% of the company’s stock.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.